United TherapeuticsUTHR

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$22.3B

Price

$512.88

Today

−0.0%

Return YTD

+5.3%

Return 1Y

+65.2%

P/E

17.0

P/S

7.1

P/B

3.5

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Pulmonary hypertensionOrgan manufacturingRare diseases

In the value chain

Products & services

PAH treatments (Tyvaso)
Remodulin & Orenitram
Organ & transplant technology

Competitors

Johnson & Johnson
Merck
Liquidia

Risks

PAH competition
Pipeline execution

Supply chain

Supplies →

The Cigna GroupCI CVS HealthCVS

← Suppliers

IQVIA HoldingsIQV

Full supply chain for UTHR →

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN BiogenBIIB Alnylam PharmaceuticalsALNY ModernaMRNA IncyteINCY

Compare UTHR

UTHR vs AMGN UTHR vs GILD UTHR vs VRTX UTHR vs REGN UTHR vs BIIB UTHR vs ALNY

See where United Therapeutics sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →